Prostate Cancer Treatments
Find Prostate Cancer Treatments
Medications for Prostate Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Prostate Cancer.
Found 25 Approved Drugs for Prostate Cancer
Docetaxel
Brand Names
Beizray, Docivyx
Docetaxel
Brand Names
Beizray, Docivyx
Form: Injection, Kit
Method of administration: Intravenous
FDA approval date: October 21, 2010
Classification: Microtubule Inhibitor
Docetaxel is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC.
Leuprolide Acetate
Brand Names
Vabrinty, Lutrate, Fensolvi, Lupron, Lupron Depot-PED, Eligard
Leuprolide Acetate
Brand Names
Vabrinty, Lutrate, Fensolvi, Lupron, Lupron Depot-PED, Eligard
Form: Injection, Kit
Method of administration: Subcutaneous
FDA approval date: January 26, 1989
Classification: Gonadotropin Releasing Hormone Receptor Agonist
VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )
Abiraterone Acetate
Brand Names
YONSA, Zytiga, Abirtega, Abiraterone, Akeega
Abiraterone Acetate
Brand Names
YONSA, Zytiga, Abirtega, Abiraterone, Akeega
Form: Tablet
Method of administration: Oral
FDA approval date: April 28, 2011
Classification: Cytochrome P450 17A1 Inhibitor
Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) metastatic high-risk castration-sensitive prostate cancer (CSPC).
Xtandi
Generic Name
Enzalutamide
Xtandi
Generic Name
Enzalutamide
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: August 31, 2012
Classification: Androgen Receptor Inhibitor
XTANDI ® is indicated for the treatment of patients with: castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer (mCSPC), non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with:, castration-resistant prostate cancer. ( 1 ), metastatic castration-sensitive prostate cancer. ( 1 ), non‑metastatic castration‑sensitive prostate cancer with biochemical recurrence at high risk for metastasis. ( 1 )
Jevtana
Generic Name
Cabazitaxel
Jevtana
Generic Name
Cabazitaxel
Form: Kit
FDA approval date: June 17, 2010
JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 )
Showing 1-5 of 25
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances